Ping Zhang, Ph.D.

Stadtman Investigator

Center for Structural Biology


Bldg. 538, Room 118 Frederick, MD 21701


Research Topics

We are a basic research laboratory that studies the structural and functional basis of protein kinase signaling. Protein kinases regulate almost every aspect of cellular function through phosphorylation of their substrates. Kinase signaling systems function as multi-domain and multi-component entities to achieve precise regulation of biological processes, and they are frequently deregulated in human diseases. The goal of my research program centers on revealing the molecular mechanisms of kinase signaling complexes that are linked to human cancers and other diseases, with a long-term goal of developing new therapeutic strategies.  Our current research objectives focus on an oncogenic PKA fusion J-PKAcα, the RAF family kinases, and the leucine rich repeat kinases (LRRKs). Toward our goals, we use interdisciplinary biochemical and structural approaches, including X-ray crystallography and cryo-electron microscopy (cryo-EM), to decipher the structure and function relationships of these challenging kinase complex systems.  We also form multidisciplinary collaborations with cell biologists and medicinal chemists.  We are interested in revealing the mechanistic details and factors critical for driving the functional activities of these kinase complexes and how these activities may be altered in pathological states. Overall, we aim to contribute to understanding fundamental principles of kinase biology.  

Oncogenic kinase fusion proteins represent an important class of cancer drivers. Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver cancer that predominantly affects adolescent and young adults with no history of liver diseases. It is driven by J-PKAcα, which is a kinase fusion chimera of the J-domain of heat shock co-chaperone DNAJB1 with PKAcα, the catalytic subunit of PKA, which has been used as a model system for the kinase family for the last 40 years. We determined the chimeric RIα2:J-PKAcα2 complex, the first for chimeric PKA holoenzymes, and its wild-type counterpart RIα2:PKAcα2 holoenzyme. Subsequent work has revealed mechanistic insights with respect to the RIα chimeric and wild-type holoenzyme conformations. Their biological relevance has been derived from analysis of these structures together with biochemical and biophysical data.  We continue to study the impact of J-domain fusion of PKA complex structures and regulation. Using the structural knowledge we have gained, we are further developing inhibitor compounds directed against this fatal pediatric cancer driver J-PKAcα for FLHCC. Additionally, our studies of J-PKAcα could provide a model for exploring the pathways of oncogenic kinase fusion transformation in other cancers.

The RAF kinases are key intermediates in the Ras signaling pathway, and they themselves are prominent drivers of human cancer. Elucidating the molecular mechanisms that regulate RAF signaling and identifying strategies to disrupt signal transmission in human disease states is a major scientific challenge. We determined cryo-EM structures of full-length BRAF complexes derived from mammalian cells: autoinhibited, monomeric BRAF:14-3-32:MEKand BRAF:14-3-32 complexes,and an inhibitor-bound, dimeric BRAF2:14-3-32 complex. These results, together with structure based mutational data, provide insights regarding how RAS binding facilitates the BRAF monomer to dimer transition.  We continue to further elucidate the structural and regulatory differences between individual members of the RAF kinase family, with a long-term view of understanding the regulation of this key oncogenic pathway.

A main focus in my group is the structure and regulation of the leucine-rich repeat kinases LRRKs, particularly LRRK2. Mutations in LRRK2 have been implicated in several diseases, most notably Parkinson’s disease (PD), and several cancers. The current understanding of LRRK2 could be greatly enhanced by structural information on LRRK2, and the complexes formed between LRRK2 and its signaling partners. Interestingly, LRRK1, the closest homologue of LRRK2, has not been shown to associate with PD or cancer. Our ongoing studies are aimed at revealing the structures and molecular mechanisms of full-length LRRK2 and LRRK1, both alone and in complex with regulatory proteins or substrates, such as the 14-3-3 proteins and the Rab small GTPases. Broadly, our goal is to gain a better understanding of how the LRRK proteins function, with an extended vision of developing therapeutic strategies to target this pathway.




Dr. Zhang received her Ph.D. training in Dr. Michael Rossmann’s lab at Purdue University in the field of biochemistry and structural virology.  Her Ph.D. project was resolving the structures of poliovirus-receptor complexes using X-ray crystallography and cryo-electron microscopy (cryo-EM).  She completed her postdoctoral training in Dr. Susan Taylor’s laboratory at UCSD, working on protein kinase PKA signaling system. She joined the Structural Biophysics Laboratory at NCI as a Stadtman Tenure Track Investigator in 2016.

Selected Publications

  1. Zhang P, Ye F, Bastidas AC, Kornev AP, Wu J, Ginsberg MH, Taylor SS. An Isoform-Specific Myristylation Switch Targets Type II PKA Holoenzymes to Membranes. Structure. 2015;23(9):1563-72.

  2. Zhang P, Knape MJ, Ahuja LG, Keshwani MM, King CC, Sastri M, Herberg FW, Taylor SS. Single Turnover Autophosphorylation Cycle of the PKA RIIβ Holoenzyme. PLoS Biol. 2015;13(7):e1002192.

  3. Taylor SS, Ilouz R, Zhang P, Kornev AP. Assembly of allosteric macromolecular switches: lessons from PKA. Nat Rev Mol Cell Biol. 2012;13(10):646-58.

  4. Zhang P, Smith-Nguyen EV, Keshwani MM, Deal MS, Kornev AP, Taylor SS. Structure and allostery of the PKA RIIβ tetrameric holoenzyme. Science. 2012;335(6069):712-6.

  5. Zhang P, Mueller S, Morais MC, Bator CM, Bowman VD, Hafenstein S, Wimmer E, Rossmann MG. Crystal structure of CD155 and electron microscopic studies of its complexes with polioviruses. Proc Natl Acad Sci U S A. 2008;105(47):18284-9.

This page was last updated on April 6th, 2022